Answers are grounded in this paper and cite their sources.
The interesting article by Fabris et al. shows that individuals screened for antiphospholipid antibodies (aPL) because of a thrombotic or obstetric history exhibit higher plateletactivating factor acetylhydrolase (PAF-AH) in plasma than control blood donors (p < 0.0001); amongst the aPL-positive participants, those lupus anticoagulant positive had higher PAF-AH than LA-negative patients (p = 0.03) and those positive for IgG anti-beta2 glycoprotein-I antibodies (aβ2GPI) presented with higher PAF-AH than patients positive for isolated IgM aβ2GPI (p = 0.03) [1]. To expand on this topic, we measured PAF-AH in 27 consecutive thrombotic primary antiphospholipid syndrome (PAPS) patients, in 17 thrombotic patients with inherited thrombophilia (IT) and in 23 healthy controls had given written consent for their plasma samples to be stored for research purposes (Table 1). In all participants, we measured IgG anticardiolipin (Cambridge Life Sciences, UK), IgG aβ2GPI (Corgenix, Denver, USA), β2GPI-oxidised low-density lipoprotein (β2GPI-oxLDL) complex and IgG anti-β2GPI-oxLDL by previously described immunoassays [2, 3], and PAF-AH by an established method [4]. Lipid profiles were normal in all participants according to measurements done two to three months earlier than the present measurements. Table 1 shows the results: IgG aPL were elevated by definition in the PAPS group but median PAF-AH was lower in PAPS compared to the other groups (p = 0.03); PAFAH correlated (Spearman rank) positively to β2GPI-oxLDL
No takes yet. Share an insight, caveat, or question.
Ames et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: